 "Medicom takeover to bolster Phillips-Medisize's drug delivery solutions")
Phillips-Medisize Corporation, a provider of manufacturing services to the medical device, diagnostics and drug delivery, has acquired Medicom Innovation Partner, a leading provider of device strategy, product design and development services with particular focus on personal connected health drug delivery device solutions to meet the needs of the rapidly growing biopharma and specialty pharmaceutical markets.
Through this acquisition, announced on June 1, 2016, Phillips-Medisize will bolster its leading position in drug delivery device solutions. Together, the combined company will have over 500 engineers across facilities in Hudson (Wisconsin, USA); Mountain View (California, USA); Hillegom (Netherlands); Struer (Denmark); Cambridge (UK) and Suzhou (China). The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable and inhalation device innovation service solutions for biopharma customers, including early device strategy, human factors engineering, product development, clinical production, full scale production and integrated supply chain management.
“This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalised oncology markets that need these products and reinforces our leading position in drug delivery device solutions. Medicom’s impressive solutions, 25 years of expertise and over 100 state-of-the-art technology accelerators, coupled with Phillips-Medisize’s scale in design to manufacturing of high to low volume production drug delivery devices, will provide customers with end-to-end integrated service solutions, resulting in increased speed to market,” said Matt Jennings, chairman, CEO and president of Phillips-Medisize.
With expertise in advanced moulding and assembly, Phillips-Medisize has become one of the leading global players in medical device and diagnostics, drug delivery, primary pharmaceutical packaging, and commercial markets. The company has annual sales of over $650 million with 80 percent of the total revenue coming from drug delivery, medical device and diagnostic products, such as: disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.
Through this acquisition, announced on June 1, 2016, Phillips-Medisize will bolster its leading position in drug delivery device solutions. Together, the combined company will have over 500 engineers across facilities in Hudson (Wisconsin, USA); Mountain View (California, USA); Hillegom (Netherlands); Struer (Denmark); Cambridge (UK) and Suzhou (China). The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable and inhalation device innovation service solutions for biopharma customers, including early device strategy, human factors engineering, product development, clinical production, full scale production and integrated supply chain management.
“This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalised oncology markets that need these products and reinforces our leading position in drug delivery device solutions. Medicom’s impressive solutions, 25 years of expertise and over 100 state-of-the-art technology accelerators, coupled with Phillips-Medisize’s scale in design to manufacturing of high to low volume production drug delivery devices, will provide customers with end-to-end integrated service solutions, resulting in increased speed to market,” said Matt Jennings, chairman, CEO and president of Phillips-Medisize.
With expertise in advanced moulding and assembly, Phillips-Medisize has become one of the leading global players in medical device and diagnostics, drug delivery, primary pharmaceutical packaging, and commercial markets. The company has annual sales of over $650 million with 80 percent of the total revenue coming from drug delivery, medical device and diagnostic products, such as: disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.